Novo Nordisk's Balancing Act: A Chinese Filing, a Failed Trial, and a Buyback That Speaks Volumes

Novo Nordisk's stock drops 13% in 30 days after Ziltivekimab trial fails, while oral Wegovy gains US traction and China reviews approval.

The Danish pharmaceutical giant is navigating one of its most consequential stretches in years, with regulatory progress in China and surging US prescriptions for its oral weight-loss drug running headlong into a clinical setback and a prominent bearish call from Deutsche Bank. The stock closed Friday at EUR 39.41, down 0.6 percent on the day and roughly 13 percent below its level of 30 days earlier.

A Clinical Miss That Complicates the Narrative

The most significant blow came on July 31, when the Phase 3 ZEUS trial for Ziltivekimab failed to meet its primary cardiovascular endpoint. The candidate, which had been viewed as a key diversification play beyond the company's GLP-1 franchise, showed no significant reduction in major adverse cardiovascular events versus placebo in patients with heart and kidney disease. The failure chips away at a pillar of the company's long-term pipeline story just as investors were looking for reasons to look past slowing growth in the core obesity franchise.

Deutsche Bank responded on August 27 by downgrading the stock from "Hold" to "Sell," trimming its price target by 9 percent to DKK 265. Analyst Emmanuel Papadakis cited the trial failure alongside limited benefits from Medicare coverage for Wegovy and the approaching patent expiry for semaglutide. The downgrade landed on the same day as the China regulatory news, underscoring the mixed signals enveloping the stock.

Just a day earlier, JPMorgan had moved in the opposite direction, lifting its price target to DKK 275 while maintaining a "Neutral" rating, buoyed by strong international growth for Ozempic and Wegovy that led the bank to raise its 2026 revenue estimates. The divergent views from two major houses capture the analytical schism over where Novo Nordisk goes from here.

China Opens the Door, But Timing Remains Unclear

On the regulatory front, China's National Medical Products Administration has accepted the company's application for the oral version of semaglutide for weight management. The regulator had already approved the drug for diabetes indications in early 2024, and a green light for obesity treatment would hand Novo Nordisk access to one of the world's largest pharmaceutical markets. The company declined to provide a timeline for approval, leaving investors to weigh the opportunity against the uncertainty.

The momentum behind the oral Wegovy pill is building elsewhere too. Weekly US prescriptions for the oral formulation have surpassed 176,000, roughly five times the volume of Eli Lilly's competing oral product Foundayo. That lead in the United States suggests Novo Nordisk retains an edge in the oral segment of the weight-loss market, even as Lilly's broader competitive pressure remains a persistent overhang.

Buybacks Continue as Management Signals Conviction

Against this backdrop, management has kept its share repurchase program running at a steady clip. Between August 17 and 21, the company bought back 1,045,000 B-shares at average prices ranging from DKK 292.60 to DKK 299.08. That brings cumulative buybacks since February 4, 2026 to 29,929,179 B-shares for approximately DKK 8.39 billion. The continued repurchases, even as the stock languishes, read as a statement from management that it considers the shares undervalued — though buybacks alone have yet to force a turnaround in sentiment.

The company also paid a dividend of USD 0.5786 per share on August 25 to shareholders of record as of August 17. On the legal front, Novo Nordisk has filed 130 federal lawsuits aimed at blocking unauthorized versions of its GLP-1 medications, signaling an aggressive defense of its franchise against copycat products.

Pipeline Work Continues on Multiple Fronts

Beyond the Ziltivekimab disappointment, the pipeline remains active. On August 12, the company launched OASIS-5, a late-stage study examining lower doses of the Wegovy pill across 62 sites in the US and Europe. The trial, expected to run until 2028, could improve the side-effect profile of the oral formulation — a factor that may prove decisive in competing against injectable rivals. Separately, subsidiary Novonesis is collaborating with Novo Nordisk on research into whether microbiome-based products can enhance the effects of GLP-1 weight-loss drugs, with initial results not expected until the second half of 2027.

In South Korea, regulators have approved the Phase 3 study plan AMAZE 13 for Zenagamtide, a dual GLP-1 and amylin receptor agonist. The company also struck a deal with Vivani Medical in July to explore an ultra-long-acting semaglutide implant.

A Stock Trading Below Its Moving Average

The shares currently sit roughly 5.7 percent below their 50-day moving average of EUR 41.81, a technical signal that reinforces the cautious near-term mood. On a year-to-date basis, the stock is down 10 percent.

Investors now have a clear date on the calendar: September 21, when Novo Nordisk hosts its capital markets day. The event is expected to provide detail on the obesity pipeline and the growth strategy for 2027, and it will likely serve as a barometer for whether management can shift the narrative away from the recent clinical miss and toward the opportunities still in front of the company.